{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:15:34Z","timestamp":1790914534113,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004205","name":"Osaka Kidney Foundation","doi-asserted-by":"publisher","award":["OKF25-0005"],"award-info":[{"award-number":["OKF25-0005"]}],"id":[{"id":"10.13039\/501100004205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite established cardiorenal benefits, concerns about urinary tract infection (UTI) risk may limit sodium-glucose cotransporter 2 inhibitor (SGLT2i) use, especially in high-risk patients. We hypothesized that urine leukocyte esterase (LE) and nitrite\u2014findings compatible with pyuria or bacteriuria\u2014predict subsequent UTI risk and modify the association between canagliflozin and UTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a post-hoc analysis of individual-participant data from two randomized, double-blind, placebo-controlled trials of canagliflozin in type 2 diabetes. The primary outcome was time to first UTI; the secondary outcome was total UTI events, analyzed with Cox and Andersen\u2013Gill models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 8614 participants, abnormal LE and nitrite were observed in 10.7% and 3.5%, respectively. After adjustment, the risk of first UTI increased with greater LE positivity [hazard ratio (HR) 1.72, 1.92, 2.81 for 1+, 2+, 3+ vs normal]. Abnormal nitrite was also associated with higher risk [HR 2.28 (1+), 1.66 (2+)]. Similar findings were observed for total UTI events. Overall, canagliflozin did not increase risk of first [HR 1.07; 95% confidence interval (CI) 0.93\u20131.22] or total UTI events (HR 1.01; 95% CI 0.86\u20131.17). LE and nitrite results did not significantly modify the effect of canagliflozin on the primary outcome. For LE, the HR for first UTI was 1.17 (95% CI 1.00\u20131.38) in the normal group and 0.94 (0.73\u20131.21) in the abnormal group (Pinteraction\u00a0=\u00a0.10). For nitrite, the HRs were 1.08 (0.94\u20131.24) and 0.92 (0.59\u20131.43), respectively (Pinteraction\u00a0= .45). For the secondary outcome, canagliflozin also did not increase the risk of total UTI events in either the abnormal LE or nitrite group [HR 0.76 (0.58\u20130.99) and 1.18 (0.79\u20131.76), respectively].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although abnormal LE and nitrite were associated with increased UTI risk, canagliflozin did not further increase this risk in these subgroups. These findings do not support routine withholding of SGLT2i in patients with dipstick findings suggestive of pyuria or bacteriuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag062","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:36:28Z","timestamp":1773491788000},"page":"1887-1898","source":"Crossref","is-referenced-by-count":1,"title":["Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-291X","authenticated-orcid":false,"given":"Yohei","family":"Doi","sequence":"first","affiliation":[{"name":"Graduate School of Medicine, The University of Osaka Department of Nephrology, , Suita, Osaka ,","place":["Japan"]},{"name":"Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine Department of Cardiology, , Toon, Ehime ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-9106","authenticated-orcid":false,"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, The University of Osaka Department of Nephrology, , Suita, Osaka ,","place":["Japan"]},{"name":"Nagoya City University Graduate School of Medical Sciences Department of Nephrology, , Nagoya, Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Fukuda-Doi","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center Department of Data Science, , Suita, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-7167","authenticated-orcid":false,"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, The University of Osaka Department of Nephrology, , Suita, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026093006065228100_bib1","doi-asserted-by":"crossref","first-page":"ofz446","DOI":"10.1093\/ofid\/ofz446","article-title":"Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection","volume":"6","author":"Carreno","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026093006065228100_bib2","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.3390\/ijerph17249427","article-title":"Time trends in Spain from 2001 to 2018 in the incidence and outcomes of hospitalization for urinary tract infections in patients with type 2 diabetes mellitus","volume":"17","author":"L\u00f3pez-de-Andr\u00e9s","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2026093006065228100_bib3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jdiacomp.2014.03.012","article-title":"Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S","volume":"28","author":"Yu","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2026093006065228100_bib4","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1007\/s00125-005-1794-3","article-title":"Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: the Fremantle Diabetes Study","volume":"48","author":"Karunajeewa","year":"2005","journal-title":"Diabetologia"},{"key":"2026093006065228100_bib5","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","article-title":"Risk factors for symptomatic urinary tract infection in women with diabetes","volume":"23","author":"Geerlings","year":"2000","journal-title":"Diabetes Care"},{"key":"2026093006065228100_bib6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2337\/dc10-0421","article-title":"Meta-analysis of the significance of asymptomatic bacteriuria in diabetes","volume":"34","author":"Renko","year":"2011","journal-title":"Diabetes Care"},{"key":"2026093006065228100_bib7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr Diab Rep"},{"key":"2026093006065228100_bib8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.7326\/ANNALS-24-00549","article-title":"Shortfalls in follow-up albuminuria quantification after an abnormal result on a urine protein dipstick test","volume":"177","author":"Xu","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026093006065228100_bib9","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026093006065228100_bib10","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee. 9","year":"2024","journal-title":"Diabetes Care"},{"key":"2026093006065228100_bib11","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026093006065228100_bib12","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.3390\/jcm13216509","article-title":"Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus","volume":"13","author":"Gorgojo-Mart\u00ednez","year":"2024","journal-title":"J Clin Med"},{"key":"2026093006065228100_bib13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026093006065228100_bib14","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"2026093006065228100_bib15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026093006065228100_bib16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026093006065228100_bib17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093006065228100_bib18","article-title":"STPHCOXRCS: Stata module to check proportional-hazards assumption using restricted cubic splines","author":"Discacciati","year":"2015"},{"key":"2026093006065228100_bib19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1001\/archinte.161.11.1421","article-title":"Consequences of asymptomatic bacteriuria in women with diabetes mellitus","volume":"161","author":"Geerlings","year":"2001","journal-title":"Arch Intern Med"},{"key":"2026093006065228100_bib20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10096-006-0148-5","article-title":"Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria","volume":"25","author":"Ribera","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026093006065228100_bib21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamainternmed.2024.1069","article-title":"Recurrent urinary tract infection in older outpatient women","volume":"184","author":"Huang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026093006065228100_bib22","first-page":"878","article-title":"The nitrite and leukocyte esterase tests for the evaluation of asymptomatic bacteriuria in obstetric patients","volume":"71","author":"Robertson","year":"1988","journal-title":"Obstet Gynecol"},{"key":"2026093006065228100_bib23","doi-asserted-by":"publisher","first-page":"e2444495","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines Group Consensus Statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026093006065228100_bib24","doi-asserted-by":"publisher","first-page":"eadh5090","DOI":"10.1126\/scitranslmed.adh5090","article-title":"Neutrophil extracellular traps protect the kidney from ascending infection and are required for a positive leukocyte dipstick test","volume":"16","author":"Stewart","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026093006065228100_bib25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026093006065228100_bib26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026093006065228100_bib27","doi-asserted-by":"publisher","first-page":"14791641211011016","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"key":"2026093006065228100_bib28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jcjd.2021.12.005","article-title":"Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: a propensity score-matched population-based cohort study","volume":"46","author":"Alkabbani","year":"2022","journal-title":"Can J Diabetes"},{"key":"2026093006065228100_bib29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/dom.13959","article-title":"A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection","volume":"22","author":"Fralick","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026093006065228100_bib30","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"2026093006065228100_bib31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026093006065228100_bib32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.ajkd.2016.08.022","article-title":"Urinary uromodulin and risk of urinary tract infections: the Cardiovascular Health Study","volume":"69","author":"Garimella","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026093006065228100_bib33","first-page":"985","article-title":"Asymptomatic bacteriuria in adults","volume":"74","author":"Colgan","year":"2006","journal-title":"Am Fam Physician"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag062\/67369092\/gfag062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1887\/67369092\/gfag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1887\/67369092\/gfag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:07:01Z","timestamp":1790762821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/10\/1887\/8524803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag062","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,3,16]]}}}